Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
N4 Pharma Plc specializes in the development of innovative drug delivery systems, particularly focusing on enhancing the bioavailability of existing drugs. Its lead product, N4P001, targets the treatment of various cancers, leveraging its proprietary delivery technology to improve therapeutic outcomes. The company operates primarily in the UK and has potential applications in global markets.
N4 Pharma generates revenue through the development and licensing of its proprietary drug delivery technology, which enhances the efficacy of existing pharmaceutical compounds. The company has a unique competitive advantage in its patented technology that significantly improves drug absorption, potentially leading to higher sales for partnered products.
Progress in clinical trials for N4P001, particularly any positive efficacy results
New licensing agreements with pharmaceutical companies
Regulatory approvals from health authorities in key markets
Market sentiment around the oncology drug development landscape
Regulatory changes affecting drug approval processes
Technological disruption in drug delivery systems
Emergence of alternative drug delivery technologies
Competitive pressure from larger pharmaceutical companies with more resources
High cash burn rate with no current revenue generation
Reliance on external funding for operational sustainability
low - The demand for pharmaceuticals is relatively inelastic, but broader economic conditions can impact funding and investment in biotech.
Minimal impact as the company is not currently generating revenue and does not have debt; however, rising rates could affect future fundraising efforts.
minimal - The company has no debt, reducing its exposure to credit market fluctuations.
growth - Investors looking for high-risk, high-reward opportunities in biotech.
high - The stock is likely to exhibit high volatility due to the binary nature of clinical trial outcomes.
